In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE _Ala63Pro mutation during treatment in a pre-XDR TB patient

Eur Respir J. 2022 Mar 24;59(3):2102102. doi: 10.1183/13993003.02102-2021. Print 2022 Mar.

Abstract

This letter describes microevolution of a pre-XDR MTB strain isolated from a pulmonary TB patient over an 18-month exposure to BDQ. MDR-TB therapies with BDQ require a functional background regimen to prevent emergence of additional resistance. https://bit.ly/3D05qT9

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics
  • Extensively Drug-Resistant Tuberculosis* / drug therapy
  • Extensively Drug-Resistant Tuberculosis* / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Mycobacterium tuberculosis* / genetics
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents